Enveda Biosciences Raises $150M in Series D
Enveda Biosciences has successfully raised $150M in a Series D at a $1.2B valuation led by FPV, Deerfield Management.
Company Overview
Enveda Biosciences is a HealthTech company headquartered in Boulder, CO, founded in 2019 with 150+ employees.
AI-powered drug discovery from plants
Fundraising Details
- Amount Raised: $150M
- Round Type: Series D
- Valuation: $1.2B
- Date: 2025-09-01
- Investors: FPV, Deerfield Management
About Enveda Biosciences
AI-powered drug discovery from plants The company is positioned in the HealthTech sector, serving a growing market with innovative solutions.
Key Information
- Headquarters: Boulder, CO
- Founded: 2019
- Team Size: 150+
- Industry: HealthTech
What This Means
This funding round demonstrates strong investor confidence in Enveda Biosciences's vision and execution. The capital will likely be used to:
- Scale Operations: Expand the team and operational capacity
- Product Development: Enhance existing products and develop new features
- Market Expansion: Enter new markets and strengthen presence in existing ones
- Technology Investment: Invest in infrastructure and technology capabilities
Industry Context
The HealthTech sector continues to attract significant investment as companies innovate to meet evolving market demands. Enveda Biosciences's successful fundraising reflects the strong fundamentals and growth potential in this space.
Valuation Milestone
Reaching a $1.2B valuation marks an important milestone for Enveda Biosciences, positioning the company among notable players in the HealthTech industry.
Looking Ahead
With this new capital, Enveda Biosciences is well-positioned to execute on its growth strategy and continue building innovative solutions in the HealthTech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.
---
This fundraising news was reported on 2025-09-01. For more information about Enveda Biosciences, visit their headquarters at Boulder, CO.
